University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without customization. However, some NK companies, such as Fate Therapeutics and Cytovia ...

A group of scientists in China has revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...

The trial investigated escalating doses of the CAR-NK cells and found that patients tolerated even the highest dose given in this trial. The investigators tested these CAR-NK cells alone in 18 ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

Unmodified natural killer (NK) cells work differently from the T-cells upon which CAR-T therapies are based – NKs are usually involved in killing cells that are infected with viruses, whereas T ...